Analysts' Actions: AXP COF CSCO HPQ VZ

Hess (HES) upgraded at Credit Suisse from underperform to neutral. $68 price target. Net asset value is improving.

HopFed Bancorp (HFBC) upgraded to buy at TheStreet Ratings.

Hewlett-Packard (HPQ) upgraded at JP Morgan from underweight to neutral. $21 price target. Headline news will likely not get worse going forward.

H&R Block (HRB) downgraded at Morgan Stanley to underweight from equal-weight. $17 price target. IRS delays and stock run creates unattractive risk reward.

Huntsman (HUN) downgraded at Wells Fargo to market perform from overweight. $17-$19 price target. Valuation call.

IBM (IBM) downgraded at JP Morgan from overweight to neutral. $197 price target. Company has relatively lower growth potential.

Incyte (INCY) upgraded at Lazard from neutral to buy. $25 price target. Jakafi should see earlier adoption.

Intuitive Surgical (ISRG) upgraded at Lazard to buy, Lazard Capital Markets said. $600 price target. Stock is attractive, following a 10% pullback.

JDS Uniphase (JDSU) downgraded at Goldman from buy to neutral, Goldman Sachs said. Valuation call, based on a $14 price target.

Louisiana-Pacific (LPX) downgraded at DA Davidson from neutral to underperform, DA Davidson said. $18 price target. Recent move is strand board prices is likely not sustainable.

Maxim (MXIM) downgraded at Credit Suisse from outperform to neutral, Credit Suisse said. $31 price target. Expect significant deterioration in the handset market.

Nucor (NUE) upgraded at Keybanc from hold to buy, Keybanc said. Company is leveraged to lagging commercial construction markets. $56 price target.

Old Dominion (ODEL) downgraded at Deutsche from buy to hold, Deutsche Bank said. Valuation call, based on a $40 price target.

Pharmacyclics (PCYC) downgraded at Lazard to neutral. Company lacks near-term catalysts.

Parexel (PRXL) upgraded at Goldman from sell to neutral, Goldman Sachs said. $36 price target. Company can continue to expand margins over the coming quarters.

Reliance Steel (RS) downgraded at Keybanc from buy to hold. Estimates also cut, given a lower pricing environment.

Sprint (S) downgraded at UBS to neutral from buy, UBS said. $6 price target. 2013 outlook/operational challenges should keep shares range bound in 1H.

Sprint downgraded at JP Morgan from overweight to neutral, JP Morgan said. $6 price target. Sales growth is decelerating.

« First ‹ Previous 1 2 3 Next › Last »